



Amended claims showing deletions and additions with the second response

1. (amended) A method of inhibiting blood supply to a tumor, comprising the steps of:

(a) locating an artery which carries major blood supply to the

tumor, said artery being one that is proximate to the tumor ;

and

[a] (b) intra-arterially injecting into the located artery a predetermined quantity of a salt solution mixture of a polyunsaturated fatty acid in the form of a salt solution of at least one polyunsaturated fatty acid chosen from linoleic acid, gamma-linolenic acid, dihomo-gamma-linolenic acid, arachidonic acid, alpha-linolenic acid, eicosapentaenoic acid, docosahexaenoic acid and cis-parinaric acid and one or more anti-angiogenic substance(s).

2. A method as in claim 1 comprising the step of causing

antiangiogenic action, wherein said polyunsaturated fatty acid is in the form of a lithium salt solution and wherein said predetermined quantity of the fatty acid is generally in a range of 0.5 mg to 50 gm.

3. (amended) A method as in claim 1 wherein step (b) comprises intra-arterially injecting [a] said predetermined quantity of a polyunsaturated fatty acid in the form of a [mixture] lithium salt solution of a polyunsaturated fatty acid,

[including at least one predetermined] wherein said anti-angiogenic substance is to the extent of 1 to 1000 mg/kg/ body weight, said [mixture] solution of polyunsaturated fatty acid further comprising a substance chosen from glycerides, esters, free acids, amides, phospholipids and salts.

4. A method as in claim 1, wherein the polyunsaturated fatty acid is in the form of a lithium salt solution of gamma-linolenic acid and eicosapentaenoic acid/docosahexaenoic acid, including a predetermined quantity of said anti-angiogenic substance chosen from: an anti-angiogenic substance naturally occurring as a protein, platelet factor-4, TNP-470, thalidomide, interleukin-12, and metalloprotease inhibitors, and a predetermined anti-cancer drug.

5. A method of treating a tumor and facilitating visualization of remission of the tumor responsive to treatment, comprising :

(a) locating an artery which carries a major portion of blood supply to

 said tumor and is adjacent to the tumor;

(b) obtaining an initial radiographic image of the tumor region;

(c) injecting into the located artery a mixture of at least

 (i) an oily lymphographic agent as a carrier containing one or more
 of anti-angiogenic substance(s)

 (ii) a lithium salt solution of at least one polyunsaturated fatty acid

chosen from linoleic acid, gamma-linolenic acid, dihomo-gamma-linolenic acid, arachidonic acid, alpha-linolenic acid, eicosapentaenoic acid, docosahexaenoic acid and cis-parinaric acid

- (d) obtaining second and subsequent radiographic images of the tumor region after predetermined lapses of time; and
- (e) comparing the initial radiographic image with the second and subsequent images to assess an extent of remission of the tumor.

6. (amended) A method as in claim 5 wherein step (c) comprises intra-arterially injecting [a] said mixture containing [element/s] components chosen from : an anti-angiogenic substance naturally as a protein, platelet factor-4, TNP-470, thalidomide, and interleukin-12, causing anti-angiogenic action by inhibiting the blood supply to the tumor, wherein further the oily lymphographic agent acts as a carrier for said anti-angiogenic substance(s), and also for the lithium salt solution of predetermined quantities of gamma-linolenic acid, eicosapentaenoic acid and/or docosahexaenoic acid.

7. (amended) A method of treating a cancerous tumor, comprising

- (a) using an oily lymphographic agent as a carrier for
 - (i) at least one polyunsaturated fatty acid chosen from a lithium salt of at least one of linoleic acid, gamma-linolenic acid, dihomo-gamma-linolenic acid,

arachidonic acid, alpha-linolenic acid, eicosapentaenoic acid, docosahexaenoic acid, and cis-parinaric acid; and,

(ii) [one] a predetermined anti-cancer drug[,] and anti-angiogenic substance(s) [which are] mixed with polyunsaturated fatty acids or [co-valently linked to] coupled with fatty acids; and,

(b) administering, by injecting into said cancerous tumor a predetermined quantity of [selected] the fatty acids, anti-cancer drug and predetermined anti-angiogenic substance in the oily lymphographic agent as a carrier.